Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Smith & Nephew plc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.43 (market cap $41.13B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 3.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Smith & Nephew plc for 120 Days on average.
| IEF | SNN | |
|---|---|---|
Market Cap | $41.13B | $11.10B |
Volume | 10,340,382 | 1,051,703 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $37.17 |
52-Week Low | $88.92 | $26.42 |
Typical Hold Time | 108 Days | 120 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.11, down 0.02% with a bearish technical outlook. The fund shows neutral oscillators but bearish moving averages, with RSI levels below 30 indicating potential oversold conditions. Recent dividend payments of $0.31-$0.33 provide income support amid market volatility. The bond market faces pressure from rising Treasury yields and inflation concerns.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current yields offer attractive entry points for income investors, persistent inflation and Fed policy uncertainty pose significant risks. Defensive positioning in fixed income suggests limited near-term upside potential.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
